Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jennifer, Ackil"'
Autor:
Alice T. Shaw, Richard B. Lanman, Justin F. Gainor, Jochen K. Lennerz, Aaron N. Hata, Anna F. Farago, Jennifer Ackil, Emily Chin, Harper Hubbeling, Beow Y. Yeap, Rebecca J. Nagy, Jessica J. Lin, Marguerite Rooney, Ibiayi Dagogo-Jack
Purpose:Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9e48e98418d9d0fff3053feff13a86
https://doi.org/10.1158/1078-0432.c.6527913.v1
https://doi.org/10.1158/1078-0432.c.6527913.v1
Autor:
Alice T. Shaw, Richard B. Lanman, Justin F. Gainor, Jochen K. Lennerz, Aaron N. Hata, Anna F. Farago, Jennifer Ackil, Emily Chin, Harper Hubbeling, Beow Y. Yeap, Rebecca J. Nagy, Jessica J. Lin, Marguerite Rooney, Ibiayi Dagogo-Jack
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02f27b4c7b3e4183579988da58f431b5
https://doi.org/10.1158/1078-0432.22471503
https://doi.org/10.1158/1078-0432.22471503
Autor:
Alice T. Shaw, Richard B. Lanman, Justin F. Gainor, Jochen K. Lennerz, Aaron N. Hata, Anna F. Farago, Jennifer Ackil, Emily Chin, Harper Hubbeling, Beow Y. Yeap, Rebecca J. Nagy, Jessica J. Lin, Marguerite Rooney, Ibiayi Dagogo-Jack
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3384f455ea48d90cfb9e0941bd7d8887
https://doi.org/10.1158/1078-0432.22471500
https://doi.org/10.1158/1078-0432.22471500
Autor:
Alice T. Shaw, Richard B. Lanman, Justin F. Gainor, Jochen K. Lennerz, Aaron N. Hata, Anna F. Farago, Jennifer Ackil, Emily Chin, Harper Hubbeling, Beow Y. Yeap, Rebecca J. Nagy, Jessica J. Lin, Marguerite Rooney, Ibiayi Dagogo-Jack
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332af61334b699155ec0f0395c0e64e7
https://doi.org/10.1158/1078-0432.22471506.v1
https://doi.org/10.1158/1078-0432.22471506.v1
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio
Autor:
Alice T. Shaw, Jochen K. Lennerz, Jessica J. Lin, Rebecca J. Nagy, Justin F. Gainor, Lorin A. Ferris, Marguerite Rooney, Richard B. Lanman, Ibiayi Dagogo-Jack, Jennifer Ackil, Emily Chin
Publikováno v:
Journal of Thoracic Oncology. 14:816-824
Introduction Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping approaches t
Autor:
Justin F. Gainor, Ginger Y. Jiang, Jennifer Ackil, Alice T. Shaw, Beow Y. Yeap, Subba R. Digumarthy, Jessica J. Lin, Nencyben Joshipura, Sandra Rincon
Publikováno v:
Journal of Thoracic Oncology. 14:683-690
Background Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK tyrosine kinase gene (ALK)-positive NSCLC. Alectinib has demonstrated robust CNS activity in both crizotinib-naive and
Autor:
Ibiayi, Dagogo-Jack, Marguerite, Rooney, Jessica J, Lin, Rebecca J, Nagy, Beow Y, Yeap, Harper, Hubbeling, Emily, Chin, Jennifer, Ackil, Anna F, Farago, Aaron N, Hata, Jochen K, Lennerz, Justin F, Gainor, Richard B, Lanman, Alice T, Shaw
Publikováno v:
Clin Cancer Res
BACKGROUND: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generat
Autor:
Michael S. Rabin, Justin F. Gainor, Ibiayi Dagogo-Jack, Alice T. Shaw, Caitlyn Helms, Alona Muzikansky, Jessica J. Lin, Jennifer Ackil, Gianluca Diubaldi, Jessica Fink, Rebecca S. Heist, Geoffrey R. Oxnard
Publikováno v:
Journal of Clinical Oncology. 38:9595-9595
9595 Background: Lorlatinib is a 3rd-generation ALK tyrosine kinase inhibitor (TKI) developed to penetrate the central nervous system (CNS) and overcome resistance to 2nd-generation (2nd-gen) ALK TKIs. In a phase II study, lorlatinib demonstrated sig
Autor:
Mandeep Banwait, Alice T. Shaw, Kelly Goodwin, Jessica J. Lin, Lecia V. Sequist, Justin F. Gainor, Zofia Piotrowska, Rebecca S. Heist, Stephen V. Liu, Nicolas Marcoux, Jennifer Ackil, Tracey E Lafferty, Sara Stevens, Elizabeth A. Krueger, Aaron N. Hata, Alona Muzikansky
Publikováno v:
Journal of Clinical Oncology. 36:e21231-e21231
e21231Background: Osimertinib (osi) is a potent, CNS-penetrant 3rd-generation EGFR TKI. Though older TKIs did not add benefit to chemo (IMPRESS, Soria et al 2015), combining osi with chemo to prolo...